ClinicalTrials.gg
Not yet recruitingNCT07163754SID_3Updated Sep 9, 2025

Use of the SiDTM v2.0 Algorithm to Assist Embiyologists in Sperm Selection During ICSI Procedures

An interventional study of Automated Sperm Selection and Conventional Sperm Selection in Male Fertility, Testicular and Sperm Parameters in Fertile and Infertile Men, sponsored by Instituto Valenciano de Infertilidad, IVI VALENCIA. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-09.

Sponsored by Instituto Valenciano de Infertilidad, IVI VALENCIA · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Infertility is defined as a failure of a couple to achieve a pregnancy after 12 or more months of unprotected intercourse. Males are found to be solely responsible for 20-30% of infertility cases but contribute to 50% of cases overall. The selection of sperm to microinject is completely subjective and there is high intra- and inter- observer variability. SiDTM v2.0 is an algorithm which analyses real-time seminal samples located at ICSI dishes. Particularly, it assesses morphology and several motility parameters of each sperm, and it assigns a categorical and numerical score to each one. Categorical scores are represented by colours: green colour for optimal sperm, yellow for good sperm, orange for medium-quality sperm and red for low-quality sperm. Numerical scores ranged from 0 to 100, with higher scores for those best-quality sperm. SiDTM v2.0 can reduce subjectivity of the sperm selection process to the maximum, selecting the optimal sperm in real time. In addition, it could help junior embryologists to perform this complex and tedious procedure, which is the sperm selection for ICSI. To carry out the study, we will conduct a prospective cohort study in a total of 100 couples. Therefore, the aim of this study is to validate SiDTM v2.0 as an useful Artificial Intelligence-tool for sperm selection; that means achieving , at least, same clinical results as sperm selection performed by the embryologist.

02

Conditions studied

  • Male Fertility
  • Testicular
  • Sperm Parameters in Fertile and Infertile Men
  • Sperm Selection

Keywords

  • Intracytoplasmatic Sperm injection
  • automated sperm selection
  • artificial intelligence
  • fertilization
  • embryo quality
03

In context

Lead sponsor

Instituto Valenciano de Infertilidad, IVI VALENCIA is the lead sponsor of 72 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with indication for ICSI.
  • Women of advanced maternal age (>35 years) in whom at least 4 oocytes in metaphase II stages are obtained in the follicular puncture, without excluding patients from the oocyte donation program.
  • Sperm obtained by masturbation with a concentration above 1 million spermatozoa/mL after sperm capacitation.
  • Normal karyotype of both partners.
  • (IC).

Exclusion criteria

Exclusion Criteria:

  • Patients diagnosed with recurrent gestational loss.
  • Semen extracted by testicular .
  • Semen samples with globozoospermia (sperm defect due to lack of acrosome) or azoospermia (absence of spermatozoa in the ejaculate).
  • Semen samples treated with pentoxifylline.
  • ICSI cycles with application of calcium ionophore. o ICSI cycles with application of calcium ionophore.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    SID

    Half of the MII oocytes obtained will be microinjected with spermatozoa selected by SiD TM

    Diagnostic Test: Automated Sperm Selection

  • Active comparator
    NO-SID

    Half of the MII oocytes obtained will be microinjected with spermatozoa selected by embriologist.

    Diagnostic Test: Conventional Sperm Selection

Interventions

  • Diagnostic testAutomated Sperm Selection

    This group of oocytes will be microinjected with sperm selected by the second version of SID TM (SID V2.0) wich analyses additional sperm parameters than first version of SID TM (SID V1.0).

  • Diagnostic testConventional Sperm Selection

    Half of the oocytes will be microinjected with sperm selected by the embryologist without SID assistance, based on the conventional and visual assesment of seminal samples located at ICSI dishes.

06

What researchers measure

Primary outcomes

  1. SID TM V2.0 VALIDATION

    The main objective of this study is to test whether assisted sperm selection using the artificial intelligence algorithm SiDTM v2.0 equals or exceeds the mean rate of useful blastocysts obtained by conventional unassisted sperm selection by SiDTM v2.0.

    Time frame: 1 year

Secondary outcomes

  1. Fertilization assesment (SID vs NO SID)

    Fertilization rate (SID VS NO SID)

    Time frame: 1 year

  2. Embryo development assesment (SID vs NO SID)

    Embryo development rate (SID VS NO SID)

    Time frame: 1 year

  3. Clinical outcomes assesment (SID vs NO SID)

    Gestation rate.

    Time frame: 1 year

  4. Clinical outcomes assesment (SID vs NO SID)

    Implantation rate

    Time frame: 1 year

  5. Clinical outcomes assesment (SID vs NO SID)

    Live birth rate.

    Time frame: 1 year

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Montjean D, Godin Page MH, Pacios C, Calve A, Hamiche G, Benkhalifa M, Miron P. Automated Single-Sperm Selection Software (SiD) during ICSI: A Prospective Sibling Oocyte Evaluation. Med Sci (Basel). 2024 Mar 27;12(2):19. doi: 10.3390/medsci12020019. PubMed 38651413 ↗
  • Mendizabal-Ruiz G, Chavez-Badiola A, Aguilar Figueroa I, Martinez Nuno V, Flores-Saiffe Farias A, Valencia-Murilloa R, Drakeley A, Garcia-Sandoval JP, Cohen J. Computer software (SiD) assisted real-time single sperm selection associated with fertilization and blastocyst formation. Reprod Biomed Online. 2022 Oct;45(4):703-711. doi: 10.1016/j.rbmo.2022.03.036. Epub 2022 Apr 10. PubMed 35989168 ↗
  • Carrión-Sisternas, L., Bori, L., Conversa, L., Viloria, T., Tejera, A. AUTOMATED REAL-TIME SPERM SELECTION FOR INTRACYTOPLASMIC SPERM INJECTION (ICSI): SIBLING OOCYTE EVALUATION. Fertility and Sterility, Volume 122, Issue 4, e350
  • Asada Y. Evolution of intracytoplasmic sperm injection: From initial challenges to wider applications. Reprod Med Biol. 2024 May 27;23(1):e12582. doi: 10.1002/rmb2.12582. eCollection 2024 Jan-Dec. PubMed 38803410 ↗

Related links

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07163754
Lead sponsor
Instituto Valenciano de Infertilidad, IVI VALENCIA
Collaborators
IVF 2.0 Limited
Responsible party
Sponsor
First posted
Sep 9, 2025
Start date
Oct 2025 (estimated)
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Sep 9, 2025

Study contacts

Marcos Meseguer, PhD
Contact
marcos.meseguer@ivirma.com
+34 963050999 ext. 11723
LAURA CARRION, Pre-Doc Trainee
Contact
laura.carrion@ivirma.com
Marcos Meseguer, PhD
principal investigator · IVIRMA Valencia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion